Alector Inc represents values of innovation, collaboration, and dedication to finding novel therapeutic treatments for neurodegenerative disorders. With a mission to improve the lives of patients, the company focuses on developing immune-modulatory therapies to target the root causes of diseases like Alzheimer's and Parkinson's. Alector Inc's corporate philosophy prioritizes scientific excellence, cutting-edge research, and a patient-centric approach. By harnessing the power of the immune system, the company aims to transform the treatment landscape and provide hope to individuals and families affected by neurodegenerative diseases. Alector Inc's commitment to scientific advancements and addressing unmet medical needs drives its mission to make a lasting impact in the field.

Alector Inc is primarily present in the United States.

Alector Inc has achieved significant milestones in its journey. The company has successfully advanced its proprietary immuno-neurology platform, focusing on developing transformative therapies for neurodegenerative diseases. A key achievement includes progressing its lead product candidates, AL002 and AL003, into clinical trials, demonstrating promising results and potential therapeutic benefits. Alector Inc has also secured strategic collaborations and partnerships with renowned pharmaceutical companies, enabling further research and development opportunities. These milestones highlight the company's dedication to innovative solutions in addressing critical unmet needs in the field of neurodegenerative disorders. Alector Inc's continued progress positions it as a leading player in the biotechnology industry, with a strong focus on improving patient outcomes.

Alector Inc is a biotechnology company founded in 2013 and is headquartered in South San Francisco, California. The company was established with a mission to develop innovative therapies to combat neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. Alector focuses on harnessing the power of the immune system to target and eliminate disease-causing proteins, with the aim of slowing down or halting disease progression. Over the years, Alector has made significant advancements in its research and development, forging strategic partnerships and collaborations to drive the development of potential breakthrough treatments. Alector Inc remains committed to making a positive impact on patients' lives by addressing the urgent needs in neurological diseases.

Alector Inc's main competitors in the market include Biogen Inc, Eli Lilly and Company, and Denali Therapeutics Inc.

Alector Inc is primarily active in the biotechnology industry.

Alector Inc's business model focuses on utilizing its expertise in immunology and neurodegenerative diseases to develop innovative therapies. The company aims to harness the power of the immune system to target dysfunctional pathways and address the underlying causes of diseases like Alzheimer's and Parkinson's. Alector Inc leverages its proprietary immuno-neurology platform to identify potential therapeutic targets and develop antibodies that modulate the immune system's response. Through strategic collaborations and clinical trials, Alector Inc aims to advance transformative treatments and improve the lives of patients suffering from neurodegenerative disorders.

Alector KGV ir -2,34.

Alector KUV ir 6,90.

AlleAktien kvalitātes vērtējums Alector ir 2/10.

gaidāmā Alector apgrozījums ir 65,68 milj. USD.

gaidāmā Alector peļņa ir -193,82 milj. USD.

Alector Inc is an innovative biotechnology company specializing in the research, development, and marketing of drugs to combat neurodegenerative diseases such as Alzheimer's and Parkinson's. The company was founded in 2013 by four leading experts in the field of neurobiology and is headquartered in South San Francisco, California, USA. Alector's business model is focused on developing groundbreaking therapies and drugs in the field of neurodegeneration. The company has several divisions, including a research team, clinical development departments, and a marketing and sales department. Alector's research team is involved in the identification and characterization of target proteins and mechanisms that are involved in the onset and progression of neurodegenerative diseases. The company uses an innovative, data-driven approach to understand the biological basis of these diseases and develop new targeted therapeutics. Alectron has developed a proprietary platform technology called "Immune Modulation Technology (IMT)", which utilizes the immune system in a unique way. IMT aims to modulate the activity of certain immune cells, called monocytes and macrophages. These cells are known to have the ability to eliminate pathogenic germs and abnormal proteins that can trigger neurodegenerative processes. However, in some cases, monocytes and macrophages themselves can produce harmful molecules and impair the body's defense mechanism against neurodegenerative diseases. Alector's approach is to selectively manipulate the activity of these cells and help them unleash their protective effect against neuropsychiatric disorders. Alector has conducted several clinical studies, including Phase 1 and Phase 2 studies with antibody products targeting neurodegenerative diseases. Currently, Alector is focusing on two core technologies. One is the so-called "Progranulin Receptor" (PGRN), which is attributed with significant therapeutic potential. The other is a model system called MET, which is also associated with neurodegenerative diseases. The company has also entered into several strategic partnerships with renowned pharmaceutical and technology companies to strengthen its portfolio of neurodegenerative therapeutics and its market position. These partnerships include collaborations with Biogen Inc. and AbbVie Inc. In summary, Alector aims to achieve a leading position in the market for neuropsychiatric diseases and deliver groundbreaking therapies for patients suffering from these often deadly and highly threatening diseases. It is based on the belief that an innovative approach combined with advanced technology and strategic partnerships offers the opportunity to have a positive impact on society and the health of millions of people worldwide.

Alector izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Alector vai uzņēmums nedod dividendes.

Alector ISIN ir US0144421072.

Alector WKN ir A2PCBM.

Alector simbols ir ALEC.

Pēdējo 12 mēnešu laikā Alector maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Alector plāno maksāt dividendes 0 USD apmērā.

Alector pašreizējā dividendu rentabilitāte ir .

Alector maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Alector pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Alector tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Alector apmērā 0 USD, kas tika izmaksāta 13.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 13.07.2024..

Pēdējās dividendes izmaksa notika 13.07.2024..

Gadā 2023, Alector izmaksāja 0 USD dividendes.

Alector dividendes tiek izmaksātas USD.